Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.8
2.31%
60%
—
-1.10%
60%
—
5 Years
Score4.8
Net Growth2.31%
Net Trend60%
Net Income Consistency—
Rev Growth-1.10%
Rev Trend60%
Revenue Consistency—
Aquestive Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 45M to $ 44M and net income went from -$ 55M to -$ 83M. Revenue increased in 3 of those 5 years; net income in 3.
Aquestive Therapeutics Inc currently holds a 5-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 4.23 | — |
1 Year2025-08-12 | $ 3.78 | 11.90% |
5 Years2021-08-12 | $ 3.82 | 10.73% |
All Time2018-07-25 | $ 16.05 | -73.64% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-07-25 |
|---|---|---|---|---|
| Price | $ 4.23 | $ 3.78 | $ 3.82 | $ 16.05 |
| Return | — | 11.90% | 10.73% | -73.64% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 50M | -$ 68M | $ 110M |
| 2025 | $ 44M | -$ 83M | $ 121M |
| 2024 | $ 57M | -$ 44M | $ 71M |
| 2023 | $ 50M | -$ 7M | $ 23M |
| 2022 | $ 47M | -$ 54M | $ 27M |
| 2021 | $ 50M | -$ 70M | $ 28M |
| 2020 | $ 45M | -$ 55M | $ 31M |
| 2019 | $ 52M | -$ 66M | $ 49M |
| IPO2018 | $ 67M | -$ 61M | $ 60M |
Explore beyond AQST
You're looking at Aquestive Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
